Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation (Q31923472)

5 July 2017

Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation (English)

1 reference

5 July 2017

Sobal G

1

1 reference

5 July 2017

Menzel EJ

series ordinal

2

1 reference

5 July 2017

Sinzinger H

series ordinal

3

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

5 July 2017

Biochemical Pharmacology

1 reference

5 July 2017

61

1 reference

5 July 2017

373-379

1 reference

5 July 2017

3

1 reference

Low density lipoprotein undergoes oxidative modification in vivo

5 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Autoantibody against oxidised LDL and progression of carotid atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Oxidatively modified human low-density lipoprotein stimulates leukocyte adherence to the microvascular endothelium in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Catalysis of lipid peroxidation by glucose and glycosylated collagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Lipid advanced glycosylation: pathway for lipid oxidation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

The role of oxidative stress in the long-term glycation of LDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Impact of a combination of a calcium antagonist and a beta-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Effects of Ca-antagonists on oxidative susceptibility of low density lipoprotein (LDL)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

LDL oxidation: therapeutic perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Differential expression of receptors for advanced glycation end products on monocytes in patients with IDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Microsomal lipid peroxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Comparative effect of ursodeoxycholic acid and calcium antagonists on the binding, uptake and degradation of LDL in isolated hamster hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Effects of PGI2 and analogues (taprostene, iloprost) on oxidation of native and glycated LDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Simulation of the induction of oxidation of low-density lipoprotein by high copper concentrations: evidence for a nonconstant rate of initiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900548-7

10.1016/S0006-2952(00)00548-7

7 January 2021

Identifiers

DOI

1 reference

5 July 2017

1 reference